生理性抗凝。对活化蛋白C的抵抗与静脉血栓栓塞。 - Suppr

Suppr

超能文献

Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.

作者信息

Dahlbäck B

机构信息

Department of Clinical Chemistry, University of Lund, Malmö General Hospital, Sweden.

出版信息

J Clin Invest. 1994 Sep;94(3):923-7. doi: 10.1172/JCI117458.

DOI:10.1172/JCI117458

PMID:8083377

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC295127/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab7a/295127/1f032b24acb1/jcinvest00021-0022-a.jpg

相似文献

Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.生理性抗凝。对活化蛋白C的抵抗与静脉血栓栓塞。

J Clin Invest. 1994 Sep;94(3):923-7. doi: 10.1172/JCI117458.

Activated protein C resistance--a major risk factor for thrombosis.活化蛋白C抵抗——血栓形成的主要危险因素。

Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):501-16.

Coagulation factor V and thrombophilia: background and mechanisms.凝血因子V与血栓形成倾向：背景与机制

Thromb Haemost. 2007 Sep;98(3):530-42.

[Resistance to activated protein C. A common genetic risk factor in venous thrombosis].[对活化蛋白C的抵抗：静脉血栓形成的常见遗传危险因素]

Lakartidningen. 1995 Sep 27;92(39):3587-90.

Plasma resistance to activated protein C in venous and arterial thrombosis.

Thromb Haemost. 1994 Oct;72(4):647.

[APC resistance. Resistance against activated Protein C, a frequent cause of congenital thrombosis susceptibility].[抗活化蛋白C（APC）抵抗。先天性血栓形成易感性的常见原因，即对活化蛋白C的抵抗]

Schweiz Med Wochenschr. 1995 Jun 24;125(25):1237-9.

[Activated protein C resistance as the cause of recurrent mesenteric venous thrombosis].[活化蛋白C抵抗作为复发性肠系膜静脉血栓形成的原因]

Ugeskr Laeger. 1996 Oct 28;158(44):6285.

Thrombophilia: some recent advances in understanding.血栓形成倾向：近期在认识方面的一些进展

J R Nav Med Serv. 1995 Winter;81(3):203-6.

Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.血浆对活化蛋白C的抵抗：静脉血栓栓塞与复方口服避孕药之间的重要联系——一篇简短综述。

Eur J Contracept Reprod Health Care. 1996 Mar-May;1(1):3-11.

Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.

Haematologica. 1998 Apr;83(4):377-8.

引用本文的文献

Cryo-EM structure of coagulation factor Va bound to activated protein C.与活化蛋白C结合的凝血因子Va的冷冻电镜结构

Blood. 2025 Jun 26;145(26):3166-3177. doi: 10.1182/blood.2025028476.

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.复方口服避孕药与静脉血栓栓塞症：风险减轻的回顾与展望。

Front Endocrinol (Lausanne). 2021 Dec 9;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021.

Multiple simultaneous venous and arterial thromboses in a patient with factor V Leiden disorder: Detection by multislice computed tomography.一名患有因子V莱顿突变症的患者同时出现多处静脉和动脉血栓形成：通过多层计算机断层扫描检测。

Interv Med Appl Sci. 2015 Mar;7(1):38-41. doi: 10.1556/IMAS.6.2014.006. Epub 2015 Mar 20.

Factor v leiden and inflammation.凝血因子V莱顿突变与炎症

Thrombosis. 2012;2012:594986. doi: 10.1155/2012/594986. Epub 2012 May 14.

The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.血栓调节蛋白类似物 Solulin 可促进血栓性中风模型中的再灌注并减少梗死体积。

J Thromb Haemost. 2011 Jun;9(6):1174-82. doi: 10.1111/j.1538-7836.2011.04269.x.

Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.视网膜分支静脉阻塞：发病机制、视觉预后及治疗方式

Curr Eye Res. 2008 Feb;33(2):111-31. doi: 10.1080/02713680701851902.

SV-IV Peptide1-16 reduces coagulant power in normal Factor V and Factor V Leiden.SV-IV肽1-16降低正常凝血因子V和凝血因子V莱顿的凝血能力。

J Transl Med. 2007 Dec 21;5:69. doi: 10.1186/1479-5876-5-69.

FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population.塞尔维亚人群中的FV莱顿突变与复发性静脉血栓栓塞风险

J Thromb Thrombolysis. 2008 Jun;25(3):284-7. doi: 10.1007/s11239-007-0059-z. Epub 2007 Jun 5.

Benign intracranial hypertension associated to blood coagulation derangements.与凝血紊乱相关的良性颅内高压

Thromb J. 2006 Dec 24;4:21. doi: 10.1186/1477-9560-4-21.

Human gene mutation in pathology and evolution.病理学与进化中的人类基因突变。

J Inherit Metab Dis. 2002 May;25(3):157-82. doi: 10.1023/a:1015621710660.

本文引用的文献

Inherited predisposition to thrombosis.遗传性血栓形成易感性。

Cell. 1993 Feb 26;72(4):477-80. doi: 10.1016/0092-8674(93)90063-v.

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.由于一种先前未被认识的机制导致的家族性血栓形成倾向，其特征为对活化蛋白C的抗凝反应不佳：活化蛋白C辅因子的预测。

Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004-8. doi: 10.1073/pnas.90.3.1004.

Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.蛋白S与因子Va的结合与凝血酶原酶的抑制相关，该抑制作用独立于活化蛋白C。

J Biol Chem. 1993 Feb 5;268(4):2872-7.

Anticoagulant protein C pathway defective in majority of thrombophilic patients.大多数血栓形成倾向患者的抗凝蛋白C途径存在缺陷。

Blood. 1993 Oct 1;82(7):1989-93.

Resistance to activated protein C as a basis for venous thrombosis.对活化蛋白C的抵抗作为静脉血栓形成的基础。

N Engl J Med. 1994 Feb 24;330(8):517-22. doi: 10.1056/NEJM199402243300801.

A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va.人活化蛋白C轻链中一个与凝血因子Va相互作用所必需的新型外部位点。

Biochemistry. 1993 Nov 30;32(47):12656-63. doi: 10.1021/bi00210a014.

The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.中风或静脉血栓形成患者以及健康受试者中对活化蛋白C抗凝反应不佳（活化蛋白C抵抗）的患病率。

Blood Coagul Fibrinolysis. 1994 Feb;5(1):51-7. doi: 10.1097/00001721-199402000-00008.

Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.九个血栓形成倾向家族中对活化蛋白C的抵抗：对蛋白S功能测定的干扰

Thromb Haemost. 1993 Dec 20;70(6):1067-71.

Mutation in blood coagulation factor V associated with resistance to activated protein C.凝血因子V突变与活化蛋白C抵抗相关。

Nature. 1994 May 5;369(6475):64-7. doi: 10.1038/369064a0.

Protein S binds to and inhibits factor Xa.蛋白S与因子Xa结合并抑制它。

Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2728-32. doi: 10.1073/pnas.91.7.2728.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验